Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Mechanisms of Drug Action
  • Published:

Extrapyramidal symptoms and antidepressant drugs: neuropharmacological aspects of a frequent interaction in the elderly

Molecular Psychiatry volume 6, pages 134–142 (2001)Cite this article

Abstract

Depression is the most prevalent functional psychiatric disorder in late life. The problem of motor disorders associated with antidepressant use is relevant in the elderly. Elderly people are physically more frail and more likely to be suffering from physical illness, and any drug given may exacerbate pre-existing diseases, or interact with other drug treatments being administered for physical conditions. Antidepressants have been reported to induce extrapyramidal symptoms, including parkinsonism. These observations prompted us to review the neurobiological mechanism that may be involved in this complex interplay including neurotransmitters and neuronal circuits involved in movement and emotion control and their changes related to aging and disease. The study of the correlations between motor and mood disorders and their putative biochemical bases, as presented in this review, provide a rationale either to understand or to foresee motor side effects for psychotropic drugs, in particular antidepressants.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Hay DP, Rodriguez MM, Franson KL . Treatment of depression in late life Clin Geriatr Med 1998 14: 33–46

    Article  CAS  PubMed  Google Scholar 

  2. Waintraub L . Depression in the aged: diagnosis and treatment Presse Medicale 1998 27: 2129–2144

    CAS  Google Scholar 

  3. Gills HS, De Vane CL, Risch SC . Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypotesis J Clin Psychopharmacol 1997 17: 377–378

    Article  Google Scholar 

  4. Miyoshi K, Ueki A, Nagano O . Managements of psychiatric symptoms of Parkinson's disease Eur Neurol 1996 36: (S1) 49–58

    Article  PubMed  Google Scholar 

  5. Tandberg E, Larsen JP, Aarsland D, Laake K, Cummings JL . Risk factors for depression in Parkinson's disease Arch Neurol 1997 54: 625–630

    Article  CAS  PubMed  Google Scholar 

  6. Hubble JP . Aging and the basal ganglia Neurol Clin 1998 16: 649–657

    Article  CAS  PubMed  Google Scholar 

  7. Volkow ND, Gur RC, Wang GJ, Fowler JS, Moberg PJ, Ding YS et al. Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals Am J Psychiatry 1998 155: 344–349

    Article  CAS  PubMed  Google Scholar 

  8. Lang AE, Lozano AM . Parkinson's disease. Second of two parts New Engl J Med 1998 339: 1130–1143

    Article  CAS  PubMed  Google Scholar 

  9. Jellinger KA . Post mortem studies in Parkinson's disease_is it possible to detect brain areas for specific symptoms? J Neural Transm Suppl 1999 56: 1–29

    Article  CAS  PubMed  Google Scholar 

  10. Berg D, Supprian T, Hofmann E, Zeiler B, Jager A, Lange KW et al. Depression in Parkinson's disease: brainstem midline alteration on transcranial sonography and magnetic resonance imaging J Neurol 1999 246: 1186–1193

    Article  CAS  PubMed  Google Scholar 

  11. Becker T, Becker G, Seufert J, Hofmann E, Lange KW, Naumann M et al. Parkinson's disease and depression: evidence for an alteration of the basal limbic system detected by transcranial sonography J Neurol Neurosurg Psych 1997 63: 590–596

    Article  CAS  Google Scholar 

  12. Willner P . The mesolimbic dopamine system as a target for rapid antidepressant action Int Clin Psychopharmacol 1997 12: S7–S14

    Article  PubMed  Google Scholar 

  13. Schildkraut JJ . The catecholamine hypothesis of affective disorders: a review of supporting evidence Am J Psychiatry 1965 122: 509–522

    Article  CAS  PubMed  Google Scholar 

  14. Van Moffaert M, Dierick M . Noradrenaline (Norepinephrine) and depression. Role in aetiology and therapeutic implications CNS Drugs 1999 12: 293–305

    Article  CAS  Google Scholar 

  15. Feighner JP . Mechanism of action of antidepressant medication J Clin Psychiatry 1999 60: (S4) 4–11

    Article  CAS  PubMed  Google Scholar 

  16. Murphy DL, Mitchell PB, Potter WZ . Novel pharmacological approaches to the treatment of depression. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: The Fourth Generation of Progress Raven Press: New York 1995 1143–1153

    Google Scholar 

  17. Mori S, Zanardi R, Popoli M, Garbini S, Brunello N, Smeraldi E et al. cAMP-dependent phosphorylation system after short and long-term administration of moclobemide J Psych Res 1998 32: 111–115

    Article  CAS  Google Scholar 

  18. Perez J, Mori S, Caivano M, Popoli M, Zanardi R, Smeraldi E et al. Effects of fluvoxamine on the protein phosphorylation system associated with rat neuronal microtubules Eur Neuropsychopharmacol 1995 S5: 65–69

    Article  Google Scholar 

  19. Nibuya M, Nestler EJ, Duman RS . Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus J Neurosci 1996 16: 2365–2372

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Popoli M, Venegoni A, Vocaturo C, Buffa L, Perez J, Smeraldi E et al. Long-term blockade of serotonin reuptake affects synaptotagmin phosphorylation in the hippocampus Mol Pharmacol 1997 51: 19–26

    Article  CAS  PubMed  Google Scholar 

  21. Leonard BE . The role of noradrenaline in depression: a review J Psychopharmacol 1997 11: S39–S47

    CAS  PubMed  Google Scholar 

  22. Garattini S, Samanin R . Biochemical hypotheses on antidepressant drugs: a guide for clinicians or a toy for pharmacologists? Psychol Med 1988 18: 287–304

    Article  CAS  PubMed  Google Scholar 

  23. Zemlan FP, Garver DL . Depression and antidepressant therapy: receptor dynamics Prog Neuro-Psychopharmacol Biol Psych 1990 14: 503–523

    Article  CAS  Google Scholar 

  24. Cowen PJ . A role for 5-HT in the action of antidepressant drugs Pharmacol Ther 1990 46: 43–51

    Article  CAS  PubMed  Google Scholar 

  25. Risch SC, Nemeroff CB . Neurochemical alterations of serotonergic neuronal systems in depression J Clin Psychiatry 1992 53: 3–7

    PubMed  Google Scholar 

  26. Banki CM, Arato M, Kilts CD . Aminergic studies and cerebrospinal fluid cations in suicide Ann New York Acad Sci 1986 487: 221–230

    Article  CAS  Google Scholar 

  27. Leonard BE . Antidepressants. Current concepts of mode of action Encephale 1991 1: 127–131

    Google Scholar 

  28. Mann JJ, Malone KM . Cerebrospinal fluid amines and higher-lethality suicide attempts in depressed inpatients Biol Psychiatry 1997 41: 162–171

    Article  CAS  PubMed  Google Scholar 

  29. Reddy PL, Khanna S, Subhash MN, Channabasavanna SM, Rao BS . CSF amine metabolites in depression Biol Psychiatry 1992 31: 112–118

    Article  CAS  PubMed  Google Scholar 

  30. Leonard BE . Mechanisms of action of antidepressants Drugs 1995 4: 1–12

    CAS  Google Scholar 

  31. Sheline YI, Bardgett ME, Jackson JL, Newcomer JW, Casernansky JG . Platelet serotonin markers and depressive symptomatology Biol Psychiatry 1995 37: 442–447

    Article  CAS  PubMed  Google Scholar 

  32. Pandey GN, Pandey SC, Janicak PG, Marks RC, Davis JM . Platelet serotonin-2 receptor binding sites in depression and suicide Biol Psychiatry 1990 28: 215–222

    Article  CAS  PubMed  Google Scholar 

  33. Langer SZ, Galzin AM . Studies on the serotonin transporter in platelets Experientia 1988 44: 127–130

    Article  CAS  PubMed  Google Scholar 

  34. D'Haenen H, De Waele M, Leysen JE . Platelet [3H]-paroxetine binding in depressed patients Psychiatr Res 1988 26: 11–17

    Article  CAS  Google Scholar 

  35. D'Hont P, Maes M, Leysen JE, Gommeren W, Scharpe S, Cosyns P . Binding of [3H] paroxetine to platelets of depressed patients: seasonal differences and effects of diagnostic classification J Affect Disord 1994 32: 27–35

    Article  Google Scholar 

  36. Gessa GL . Dysthymia and depressive disorders—dopamine hypothesis Eur Psychiatry 1996 11: S123–S127

    Article  Google Scholar 

  37. Sachdev P, Aniss AM . Slowness of movement in melancholic depression Biol Psychiatry 1994 35: 253–262

    Article  CAS  PubMed  Google Scholar 

  38. Rampello L, Nicoletti F, Nicoletti F . Dopamine and depression. Therapeutic implications CNS Drugs 2000 13: 35–45

    Article  CAS  Google Scholar 

  39. Barili P, De Carolis G, Zaccheo D, Amenta F . Sensitivity to ageing of the limbic dopaminergic system: a review Mech Ageing Devel 1998 106: 57–92

    Article  CAS  Google Scholar 

  40. Brown AS, Gershon S . Dopamine and depression J Neural Transm 1993 91: 75–109

    Article  CAS  Google Scholar 

  41. Kostic VS, Djuricic BM, Covickovic-Sternic N, Bumbasirevic L, Nikolic M, Mrsulja BB . Depression and Parkinson's disease: possible role of serotonergic mechanisms J Neurol 1987 234: 94–96

    Article  CAS  PubMed  Google Scholar 

  42. Ugedo L, Grenhoff J, Svensson TH . Ritanserin, a 5-HT2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition Psychopharmacology 1989 98: 45–50

    Article  CAS  PubMed  Google Scholar 

  43. Rosenstock L, Keifer M, Daniell WE, McConnell R, Claypoole K . Chronic central nervous system effects of acute organophosphate pesticide intoxication Lancet 1998 338: 223–227

    Article  Google Scholar 

  44. Kaufer D, Friedman A, Seidman S, Soreq H . Acute stress facilitates long-lasting changes in cholinergic gene expression Nature 1998 393: 373–377

    Article  CAS  PubMed  Google Scholar 

  45. Casey DE . Tardive dyskinesia Western J Med 1990 153: 535–541

    CAS  Google Scholar 

  46. Leo RJ, Lichter DG, Hershey A . Parkinsonism associated with fluoxetine and cimetidine: a case report J Psych Neurol 1995 8: 231–233

    CAS  Google Scholar 

  47. Hornykiewicz O . Neurotransmitters changes in human brain during aging. In: Govoni S, Battaini F (eds) Modification of Cell to Cell Signals During Normal and Pathological Aging NATO ASI series, Springer Verlag: Heidelberg 1987 169–182

    Chapter  Google Scholar 

  48. Barucha KJ, Sethi KD . Complex movement disorders induced by fluoxetine Mov Disord 1996 3: 324–326

    Article  Google Scholar 

  49. Clayton AH . Antidepressant-induced tardive dyskinesia: review and case report Psychopharmacol Bull 1995 31: 259–264

    CAS  PubMed  Google Scholar 

  50. Mander A, McCausland M, Workman B, Flamer H, Christophidis N . Fluoxetine induced dyskinesia Aust NZ J Psych 1994 28: 328–330

    Article  CAS  Google Scholar 

  51. Hauser RA, Zesiewicz T . Sertraline for the treatment of depression in Parkinson's disease Mov Disord 1997 12: 756–759

    Article  CAS  PubMed  Google Scholar 

  52. Vandel P, Bonin B, Leveque E, Sechter D, Bizouard P . Tricyclic antidepressant-induced extrapyramidal side effects Eur J Pharmacol 1997 7: 207–212

    CAS  Google Scholar 

  53. Koukopoulos A, Koukopoulos A . Agitated depression as a mixed state and the problem of melancholia Psychiatr Clin North Am 1999 22: 547–564

    Article  CAS  PubMed  Google Scholar 

  54. Heninger GR, Charney DS . Mechanism of action of antidepressant treatments: implication for etiology and treatment of depressive disorders. In: Meltzer H (ed) Psychopharmacology: The Third Generation of Progress Raven Press: New York 1987 535–554

    Google Scholar 

  55. Caccia S . Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications Clin Pharmacokinet 1998 34: 281–302

    Article  CAS  PubMed  Google Scholar 

  56. De Montis G, Devoto P, Gessa GL, Meloni D, Porcella A, Saba P et al. Central dopaminergic transmission is selectively increased in the limbic system of rats chronically exposed to antidepressants Eur J Pharmacol 1990 180: 31–35

    Article  CAS  PubMed  Google Scholar 

  57. Kozell L, Sandyk R, Wagner GC, Fisher H . The effects of L-tryptophan on haloperidol-induced movement disorder in the rat Life Sci 1987 41: 1739–1744

    Article  CAS  PubMed  Google Scholar 

  58. Skolnick P, Layer RT, Popik P, Nowak G, Paul IA, Trullas R . Adaption of N-methil-D-aspartate (NMDA) receptors following antidepressant treatment: implication for the pharmacotherapy of depression Pharmacopsychiatry 1996 29: 23–33

    Article  CAS  PubMed  Google Scholar 

  59. Coukell AJ, Spencer CM, Benfield P . Amisulpride. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia Drugs 1996 6: 237–256

    CAS  Google Scholar 

  60. Di Giovanni G, Di Mascio M, Di Matteo V, Esposito E . Effects of acute and repeated administration of amisulpride, a dopamine D2/D3 receptor antagonist, on the electrical activity of midbrain dopaminergic neurons J Pharmacol Exp Ther 1998 287: 51–57

    CAS  PubMed  Google Scholar 

  61. Perrault GH, Depoortere R, Morel E, Sanger DJ, Scatton B . Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity J Pharmacol Exp Ther 1997 280: 73–82

    CAS  PubMed  Google Scholar 

  62. Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity J Pharmacol Exp Ther 1997 280: 83–97

    CAS  PubMed  Google Scholar 

  63. Noble S, Benfield P . Amisulpride. A review of its clinical potential in dysthymya and double depression Drugs 1998 10: 1–11

    Google Scholar 

  64. Boyer P, Lecubrier Y, Stalla-Bourdillon A, Fleurot O . Amisulpride versus amineptine and placebo for the treatment of dysthymia Neuropsychobiology 1999 39: 25–32

    Article  CAS  PubMed  Google Scholar 

  65. Lecubrier Y, Boyer P, Turjanski S, Rein W . Amisulpride versus imipramine and placebo in dysthymia and major depression J Affect Disord 1997 43: 95–103

    Article  Google Scholar 

  66. Smeraldi E . Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission. A double-blind, comparative study J Affect Disord 1998 48: 47–56

    Article  CAS  PubMed  Google Scholar 

  67. Souery D, Amsterdam J, DeMontigny C, Lecubrier Y, Montgomery S, Lipp O et al. Treatment resistant depression: methodological overview and operational criteria Eur Neuropsychopharmacol 1999 9: 83–91

    Article  CAS  PubMed  Google Scholar 

  68. Pehek EA . Local infusion of the serotonin antagonists ritanserin or ICS 205,930 increases in vivo dopamine release in the rat medial prefrontal cortex Synapse 1996 24: 12–18

    Article  CAS  PubMed  Google Scholar 

  69. Ng NK, Lee HS, Wong PTH . Regulation of striatal dopamine release through 5-HT1 and 5-HT2 receptors J Neurosci Res 1999 55: 600–607

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Experimental and Applied Pharmacology, University of Pavia, Pavia, Italy

    S Govoni, M Racchi & E Masoero

  2. Department of Neurology, Institute San Raffaele, Milano, Italy

    M Zamboni & L Ferini-Strambi

Authors
  1. S Govoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Racchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E Masoero
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Zamboni
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L Ferini-Strambi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Govoni.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Govoni, S., Racchi, M., Masoero, E. et al. Extrapyramidal symptoms and antidepressant drugs: neuropharmacological aspects of a frequent interaction in the elderly. Mol Psychiatry 6, 134–142 (2001). https://doi.org/10.1038/sj.mp.4000801

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.mp.4000801

Keywords

This article is cited by

Search

Advanced search

Quick links